Semaglutide real-world data show 40% fewer asthma attacks in ERS study
Biopharma teams now have a strong observational signal that semaglutide could address asthma and COPD exacerbations, but a new indication will require prospective randomized trials. The findings may shape GLP-1 lifecycle strategies and respiratory pipeline investment.
Source: turnto23.com · abc15.com